520
Participants
Start Date
December 8, 2016
Primary Completion Date
June 13, 2022
Study Completion Date
August 10, 2022
AMPLATZER™ LAA Occluder
The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
Instituto Cardiovascular de Rosario, Rosario
Hôpital Civil Marie Curie, Lodelinsart
Hospital Clinic I Provincial de Barcelona, Barcelona
Ospedale San Giovanni Bosco, Torino
Segeberger Kliniken GmbH, Bad Segeberg
Hospital Universitario Puerta de Hierro, Majadahonda
Università degli Studi di Padova, Padua
Hospital Universitario de Salamanca, Salamanca
St. Marien-Hospital-Bonn, Bonn
Cardioangiologisches Centrum am Bethanien Krankenhaus, Frankfurt am Main
Azienda Ospedaliera Monaldi, Napoli
Zentralklinik Bad Berka GmbH, Bad Berka
Hospital Clinico San Borja Arriarán, Santiago
Royal Columbian, New Westminster
Vancouver General Hospital, Vancouver
St. Paul's Hospital, Vancouver
Ottawa Heart Institute, Ottawa
St. Michael's Hospital, Toronto
Montreal Heart Institute, Montreal
CHUM, Montreal
The Royal Victoria Hospital, Montreal
Instituto Nacional del Torax, Providencia
Lead Sponsor
Abbott Medical Devices
INDUSTRY